Top Nephrology Research Papers

Overall: A large, precise randomized-trial meta-analysis supports blood-pressure lowering to prevent major cardiovascular events throughout CKD, but absent absolute effects and harms limit conclusions about net benefit.

Overall: A large randomized trial supports meaningful kidney and possible survival benefits from semaglutide in a highly relevant primary-care population, though the subgroup design and absent safety information limit certainty about net benefit.

Overall: Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis. — Strong pooled randomized evidence shows a precise, moderate reduction in major kidney outcomes with similar overall safety, although absolute benefit and treatment burden are incompletely reported and regimen heterogeneity limits a uniform practice directive.

Overall: This well-conducted US randomised trial found clinically meaningful improvements in dialysis-access function with ATEV, but more interventions, limited follow-up, and unresolved implementation issues reduce its overall impact.

Overall: This large US observational study suggests apixaban is safer and more effective than warfarin in advanced CKD, but it does not demonstrate a clear net outcome advantage over no anticoagulation.

Overall: Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease: The TRACK Randomized Clinical Trial found no cardiovascular benefit and significantly more major bleeding in a rigorous randomized trial, supporting avoidance of this strategy in advanced CKD.

Overall: A clinically relevant systematic review supports several practical strategies for preventing recurrent calcium stones, but low-certainty evidence, absent absolute effects, and important evidence gaps limit confidence and practice-changing impact.

Overall: A large matched cohort links prompt emergency evaluation of severe outpatient hyperkalemia with lower short-term mortality, but residual confounding, unreported absolute effects, and unmeasured referral burdens limit causal and practice-changing certainty.

Overall: A large, prespecified pooled analysis found a credible but modest reduction in adjudicated sudden death, with limited absolute-benefit and safety information and only moderate potential to change current practice.

Overall: This large randomized-trial meta-analysis evaluates definitive mortality outcomes and supports cardiovascular mortality benefit, but the neutral all-cause result, absent absolute effects and harms, and exploratory subgroup findings limit its incremental practice impact.